Societies

Over 500 attendees for 2023 American Society of Clinical Oncology (ASCO) Best of ASCO meeting in Seattle – Ishwaria Subbiah

Photo from Ishwaria Subbiah, MD, MS / LinkedIn

Aug 8, 2023, 19:05

Over 500 attendees for 2023 American Society of Clinical Oncology (ASCO) Best of ASCO meeting in Seattle – Ishwaria Subbiah

⏱️ July reflections — Over 500 attendees for the 2023 American Society of Clinical Oncology (ASCO) Best of ASCO meeting in Seattle. Chair Dr. Soni Smith MD curated a superb 2-day concise, practical, high-value recap of ASCO23 designed for frontline oncologists.

Such a pleasure to be a part of the event and share these key ASCO23 findings in my talk on the state of cancer care & biomarker testing:
🔸Staggering administrative burden for physicians & patients
🔸Inequities in biomarker testing
🔸Biomarker testing timing matters
🔸1L matched therapy matters
🔸Medical debt kills

The recap:
🔸Staggering administrative burden for physicians and patients🔸
▪️Abs 1504: 96.3% of oral anticancer drugs required prior authorization in 2019, compared to 52.8% in 2010.

🔸Inequity in biomarker testing🔸
▪️Abs 6508: Black/Latinx less likely to get timely biomarker testing — testing rates ~ 8% lower. Provider-level analysis shows this gap to be mostly due to physicians who were low testers across the board in their practice

🔸Biomarker testing timing matters🔸
▪️Abs 6506: Those w prior negative single gene testing had doubled the subsequent test cancellations of comprehensive genomic profiling due to tissue insufficiency and increased DNA extraction failures.

🔸1L matched therapy matters!🔸
▪️Abs 6507: PFS & OS significantly INFERIOR in pts w aNSCLC started on 1L non-targeted therapy but NOT switched within 42d of NGS showing actionable aberration.

🔸Medical debt kills🔸
▪️Abs 6503: 1 in 5 patients w cancer had an adverse financial event (AFE) in 1st 2 yrs after diagnosis.
▫️AFE: 3rd-party collections, charge-offs, delinquent mortgage payments, tax liens, foreclosures, and repossessions
▫️These pts w an AFE had a higher risk for death – even after adjusting for sociodemographic and clinical factors. HR 1.22, 95% CI, 1.145-1.299, p <0.001. Older adults were particularly at risk.

Catch this year’s Best of ASCO recordings online and mark your calendars to attend next year.
🔗https://lnkd.in/gY8ZnR-X

Source: